Fri, Aug 1, 2014, 7:31 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Astex Pharmaceuticals, Inc. Message Board

  • abby_normal_2009 abby_normal_2009 Jun 9, 2013 3:05 PM Flag

    Astex Pharmaceuticals Has a Catalyst-Driven Year Ahead (Part IV)

    It’s worth noting that Dacogen may face generic competition this year, a detriment to sales, but generic Dacogen coming to the market is known, and if trial data supports SGI-110’s superiority (Phase II data later this year), generic Dacogen may not be relevant to the long-term story. Importantly, Dacogen is not approved for AML in the U.S., thus, there remains an exclusive market opportunity for SGI-110 in this indication. And, Dacogen retains exclusivity in the EU for AML through 2022. Despite the generic threat, SGI-110 has two potential opportunities in the MDS and AML markets: as a better agent in first-line treatment (if superior to Dacogen and/or Celgene’s (CELG) Vidaza), or if it demonstrates activity in relapsed or refractory patients it would become the go-to second-line therapy, as there are currently none approved.

    Given its numerous catalysts this year and robust financials, which is a preferred in the biotech space, we believe ASTX provides an opportunity for investors this year. However, chasing the stock in the mid-$5 range may not be wise, so entering slowly and on pullbacks makes the most sense. RBC’s recent $9 target for ASTX is a little stretched in our opinion (without Phase II data), although we agree with the attribution of ~$2/share for Dacogen royalties (4x ~$50M sales after U.S. generic competition), $4 for SGI-110, and roughly $1.21/share for cash (although some of this capital will be used this year). We consider the rest of the pipeline a free option in the stock. Given the momentum that surrounds oncology meetings like AACR, ASCO, ESMO and ASH, we believe there’s at least a dollar of upside left in ASTX from current levels. As a result, we think the ASTX story will continue to gain visibility in the coming weeks, taking the stock higher.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.